Finalizing development of the Industry’s first blood-based test for Alzheimer’s Disease (AD)and Mild Cognitive Impairment (MCI).
ForeSight Dx has licensed a new and highly unique protein-based biomarker for the early detection of Alzheimer’s disease and mild cognitive impairment. NIH funded studies have shown this biomarker to be significantly more accurate than the Aβ biomarkers currently on the market. This test can be used with patient samples of either cerebrospinal fluid, or blood. No blood-based test for AD exists in the marketplace today.